Elite Pharmaceuticals, Inc. Amortization of Debt Issuance Costs
Elite Pharmaceuticals, Inc. (ELTP) reported Amortization of Debt Issuance Costs of $73.10 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-13
- Elite Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2026-06-30 was $73.10K, a 54.00% decline year-over-year.
- Elite Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2026-03-31 was $75.06K, a 60.25% decline year-over-year.
- Elite Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was $80.20K, a 3.35% increase year-over-year.
- Elite Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $82.47K, a 67.68% decline year-over-year.
- Elite Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2026 was $396.66K, a 48.64% decline from fiscal 2025.
- Elite Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2025 was $772.37K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $73.10K 10-Q · filed 2026-08-13 | $148.17K derived: sum of 2 quarters · filed 2026-08-13 | $228.37K derived: sum of 3 quarters · filed 2026-08-13 | $310.84K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $75.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $155.27K derived: sum of 2 quarters · filed 2026-06-29 | $237.74K derived: sum of 3 quarters · filed 2026-06-29 | $396.66K 10-K · filed 2026-06-29 |
| 2025-12-31 | $80.20K 10-Q · filed 2026-02-17 | $162.67K derived: sum of 2 quarters · filed 2026-02-17 | $321.60K 10-Q · filed 2026-02-17 | $510.44K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $82.47K 10-Q · filed 2025-11-14 | $241.40K 10-Q · filed 2025-11-14 | $430.24K derived: sum of 3 quarters · filed 2026-08-13 | $507.85K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $158.93K 10-Q · filed 2026-08-13 | $347.77K derived: sum of 2 quarters · filed 2026-08-13 | $425.38K derived: sum of 3 quarters · filed 2026-08-13 | $680.51K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $188.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $266.45K derived: sum of 2 quarters · filed 2026-06-29 | $521.59K derived: sum of 3 quarters · filed 2026-06-29 | $772.37K 10-K · filed 2026-06-29 |
| 2024-12-31 | $77.61K 10-Q · filed 2026-02-17 | $332.74K derived: sum of 2 quarters · filed 2026-02-17 | $583.52K 10-Q · filed 2026-02-17 | |
| 2024-09-30 | $255.14K 10-Q · filed 2025-11-14 | $505.92K 10-Q · filed 2025-11-14 | ||
| 2017-09-30 | $3.54K 10-Q · filed 2018-11-09 | $7.09K 10-Q · filed 2018-11-09 |